Kyverna Therapeutics, Inc. (KYTX) Financial Analysis & Valuation | Quarter Chart
Kyverna Therapeutics, Inc. (KYTX)
KYTXPrice: $8.1
Fair Value: 🔒
🔒score
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and ... more
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell t... more
Description
Shares
| Market Cap | $354.71M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Warner Biddle |
| IPO Date | 2024-02-09 | CAGR | — |
| Employees | 112 | Website | kyvernatx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
KYTX chart loading...
Fundamentals
Technicals
| Enterprise Value | $121.39M | P/E Ratio | -2.17 |
| Forward P/E | -3.3 | PEG Ratio | — |
| P/S Ratio | 212066.16 | P/B Ratio | 2331.79 |
| P/CF Ratio | -3023.56 | P/FCF Ratio | -2993.94 |
| EPS | $-3.73 | EPS Growth 1Y | 21.17% |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | inf% | Gross Margin | -1.06% |
| Operating Margin | -84.8% | Profit Margin | -78.41% |
| ROE | -0.65% | ROA | -0.7% |
| ROCE | -0.92% | Current Ratio | 5.39 |
| Quick Ratio | 5.39 | Cash Ratio | 1.34 |
| Debt/Equity | 0.03 | Interest Coverage | -1751.32 |
| Altman Z Score | 1.18 | Piotroski Score | 2 |